We research innovative therapeutics to improve quality of life.
Focus areas
Daewoong Pharmaceutical focuses on Oncology and Immunology & Inflammation as strategic priorities, leading global drug discovery and development through innovative therapies.
- Oncology
- Immunology & Inflammation
Oncology Research at Daewoong Begins with the Patient
We view cancer not merely as a disease to be eradicated, but as one to be managed over the long term. Our goal is to develop personalized therapies that empower patients to lead better lives.
To achieve this, we identify effective targets based on a deep pathophysiological understanding of the entire cancer continuum—from initiation and progression to resistance—and explore optimal treatment strategies using diverse therapeutic modalities.
We also leverage molecular profiling and biomarkers to identify patients most likely to respond to treatment. This approach enhances efficacy while minimizing unnecessary toxicity, advancing the realization of precision medicine.
Core Competency
Defining new paradigms in treatment through advanced technology and differentiated research
Core Competency 01
Accelerating Clinical Entry for Drug Candidates
Daewoong IND-accelerated Track (DI-ACT) Platform
Through its proven DI‑ACT platform, Daewoong Pharmaceutical can efficiently shorten the timeline from candidate identification to IND filing.
In collaborative research conducted through open collaboration, we also apply this platform to create win‑win strategies with partners.
Fast Clinical Entry Through End‑to‑End Drug Development
A DI‑ACT Strategy Built on Two Consecutive Years of New Drug Launches
End‑to‑End
Drug Development Process- Ensuring reliable, high‑quality data
- Establishing robust nonclinical and CMC studies at each stage
Pre‑IND Brief Document /
CTD Readiness- Developing a strategy for entry
into overseas clinical trials
- Developing a strategy for entry
Accelerated IND Submission
after Candidate Identification- Strengthening global competitiveness through rapid clinical entry (DI‑ACT)
DI-ACT (Daewoong IND-Accelerated Track)
Core Competency 02
AI‑Based Drug Discovery
Daewoong bridges the gap between AI and biological validation,
enhancing the efficiency and likelihood of success in drug development through collaboration.
Daewoong AI System (DAISY)
The Daewoong AI System (DAISY) accelerates drug development by providing an integrated platform that supports candidate identification, structure optimization, and ADMET prediction end‑to‑end.
01
Candidate Compound
Exploration
- A molecular‑model database of 800 million compounds
02
Candidate
Identification
- AI‑based virtual screening system that enhances the probability of discovering promising drug candidates
03
Structure‑Based Drug
Design- Analysis of protein–ligand complexes and molecular dynamics (MD) simulations
- Support for hit‑to‑lead and lead optimization
04
Integrated ADME/T
Prediction
- Multi‑dimensional assessment based on predictive models (solubility, BBB penetration, hERG inhibition, etc.)
- Visualization through radar charts and support for candidate optimization
Core Competency 03
Antibody-based biologics
We are continuously strengthening our research capabilities in antibody‑based biologics to more precisely control the complex mechanisms of disease and enhance selective therapeutic effects.
In particular, we are developing patient‑tailored, differentiated therapies that address complex disease mechanisms by using multi‑antibody approaches to simultaneously modulate multiple targets and pathways.
Many intractable diseases arise from abnormalities in multiple biological pathways.
Daewoong Pharmaceutical selects optimal target combinations and applies diverse antibody formats along with advanced engineering technologies to enhance both the innovative profile and clinical value of its medicines.
Drawing on diverse antibody formats, Fc engineering, and the modulation of binding affinity and specificity, we focus on areas such as the degradation of extracellular disease‑associated proteins, T‑cell redirection, and tissue‑specific drug delivery.
Guided by a deep understanding of disease pathophysiology, we aim to develop medicines that overcome the limitations of existing therapies.